[18F]PI-2620
Drug timelines are a Plus or Pro feature.
7 regulatory and trial events tracked for [18F]PI-2620, covering 2023-09-06 to 2026-01-07. Get the full timeline:
Most recent: Clinical Trial Update: [18F]PI-2620 Phase 3 Histopathological Study [Phase 3]